Amgen's Revenue per Share for the
three
months ended in Jun. 2023 was $13.01.
During the past 12 months, Amgen's average Revenue per Share Growth Rate was 4.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 8.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 9.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 8.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Amgen was 121.70% per year. The lowest was 5.80% per year. And the median was 15.20% per year.
Competitive Comparison
For the Drug Manufacturers - General subindustry, Amgen's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen 3-Year Revenue Growth Rate Distribution
For the Drug Manufacturers industry and Healthcare sector, Amgen's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Amgen's 3-Year Revenue Growth Rate falls into.
Amgen 3-Year Revenue Growth Rate Calculation
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Amgen 3-Year Revenue Growth Rate Related Terms
Thank you for viewing the detailed overview of Amgen's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amjevita (biosimilar Humira).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
5.3(1.99%) Volume: 2,792,147 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
AMGN has been successfully added to your 